Here are two key passages from the article flagged above, separated by added bullets:

• A superbug is a bacterium or fungi that is resistant to clinical antimicrobials. They are increasingly common. Right now, for instance, the percentage of clinical isolates of Enterobacteriales (which includes things like Salmonella and E. coli) that are known to be resistant is around 35%.

• … we need to discover and develop novel classes of antibiotics. The last time a new class of antibiotics hit the market was in 1984. The fundamental problem is that they’re not profitable to develop, compared to say a cancer drug. You can go to the drugstore and get a course of amoxicillin for $8. We need programs that reward industry and academic labs like ours for doing the early research.